A new HIV-1 latency reversing agent activating HIV-Tat
Tong, P. B. V.; Marty, L.; Chekrit, N.; Pugniere, M.; Peloponese, J.-M.; Bouhnik, C.; TUAILLON, E.; Makinson, A.; Chaloin, L.; Beaumelle, B.
Show abstract
Despite its efficiency to prevent viral multiplication, antiretroviral therapy does not affect HIV-1 latently-infected cells. These cells do not produce significant amounts of viruses and constitute HIV-1 reservoir. To purge this long-lived viral reservoir, the "shock and kill" strategy relies on the use of latency reversing agents (LRAs) to induce activation of latent cells. All LRAs developed until now target cellular proteins and are therefore not specific for HIV-infected cells. Here we present a new LRA that binds and activates HIV-1 Tat which is the key regulator for viral transcription and latency reversal. This molecule termed D10 was designed to bind to the major groove of the Tat protein, and found to activate Tat transcriptional activity by stabilizing the HIV transcription complex. This LRA induces strong HIV production by latent cell lines and latent cells from people living with HIV-1. On latent cells from PBMCs, D10 is active at [~]50 nM, the concentration required to stabilize HIV transcription complex. D10 is the first Tat activator available and the first LRA that targets an HIV protein.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Dual Role of Glycosylation in Resistance to CD4-binding Site Broadly Neutralizing Antibodies 94%
- Identification of an antiretroviral small molecule that appears to be a host-targeting inhibitor of HIV-1 assembly 94%
- Interferon-inducible miR-128 modulates HIV-1 replication by targeting TNPO3 mRNA 93%
Similar papers in this journal
- Th17 cell master transcription factor RORC2 regulates HIV-1 gene expression and viral outgrowth 93%
- Efficient packaging of HIV-1 genomes via recognition of its adenosine-rich content by a heterologous RNA-binding domain 92%
- Mechanistic Insights into Dengue Virus Inhibition by a Clinical Trial Compound NITD-688 92%
Similar papers in this journal
- Mechanistic insights and in vivo HIV suppression by the BRD4-targeting small molecule ZL0580 93%
- Discovery of a potent anti-Zika virus benzamide series targeting the viral protein NS4B 93%
- NRF2 activators inhibit influenza A virus replication by interfering with nucleo-cytoplasmic export of viral RNPs in an NRF2-independent manner 93%
Similar papers in this journal
Similar papers in this journal
- HIV-Induced Sialoglycans on Infected Cells Promote Immune Evasion from Myeloid Cell-Mediated Killing 93%
- Structure-function Analyses Reveal Key Molecular Determinants of HIV-1 CRF01_AE Resistance to the Entry Inhibitor Temsavir 93%
- Structural analysis of the SARS-CoV-2 methyltransferase complex involved in coronaviral RNA cap creation 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.